Aslan Pharmaceuticals Ltd Stock Performance
| ASLN Stock | USD 0.47 0.01 2.17% |
Aslan Pharmaceuticals holds a performance score of 5 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -1.62, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Aslan Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Aslan Pharmaceuticals is expected to outperform it. Use Aslan Pharmaceuticals sortino ratio and the relationship between the downside variance and market facilitation index , to analyze future returns on Aslan Pharmaceuticals.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Aslan Pharmaceuticals Ltd are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady essential indicators, Aslan Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:5 | Last Split Date 2023-03-13 |
1 | ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors | 03/06/2024 |
2 | ASLAN Pharmaceuticals Announces 5 Million Registered Direct Offering | 03/12/2024 |
3 | Aslan Pharma stock target cut to 10 on financing dilution By Investing.com - Investing.com | 03/13/2024 |
4 | HC Wainwright Lowers ASLAN Pharmaceuticals Price Target to 9.00 - Defense World | 03/19/2024 |
5 | ASLN Stock Quote Price and Forecast - CNN | 03/22/2024 |
6 | Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference Skin Diseases, Conditions and Disorder... | 03/27/2024 |
7 | Are Medical Stocks Lagging ASLAN Pharmaceuticals This Year | 04/09/2024 |
8 | ASLAN Pharmaceuticals GAAP EPADS of -0.78 | 04/12/2024 |
9 | ASLAN Pharmaceuticals faces Nasdaq delisting over equity deficit | 04/19/2024 |
10 | Eblasakimab shows promise in atopic dermatitis study | 04/22/2024 |
| Begin Period Cash Flow | 56.9 M |
Aslan |
Aslan Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 60.00 in Aslan Pharmaceuticals Ltd on January 26, 2024 and sell it today you would lose (13.00) from holding Aslan Pharmaceuticals Ltd or give up 21.67% of portfolio value over 90 days. Aslan Pharmaceuticals Ltd is currently generating 1.5387% in daily expected returns and assumes 23.806% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Aslan, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aslan Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aslan Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aslan Pharmaceuticals Ltd, and traders can use it to determine the average amount a Aslan Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0646
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ASLN | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 23.81 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.54 actual daily | 30 70% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 5 95% of assets perform better |
Based on monthly moving average Aslan Pharmaceuticals is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aslan Pharmaceuticals by adding it to a well-diversified portfolio.
Aslan Pharmaceuticals Fundamentals Growth
Aslan Stock prices reflect investors' perceptions of the future prospects and financial health of Aslan Pharmaceuticals, and Aslan Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aslan Stock performance.
| Return On Equity | -4.27 | ||||
| Return On Asset | -0.64 | ||||
| Operating Margin | (3.64) % | ||||
| Current Valuation | 262.95 M | ||||
| Shares Outstanding | 22.63 M | ||||
| Price To Earning | (11.50) X | ||||
| Price To Book | 2.14 X | ||||
| Price To Sales | 0.94 X | ||||
| Revenue | 12 M | ||||
| Gross Profit | 79.82 M | ||||
| EBITDA | (43.39 M) | ||||
| Net Income | (44.22 M) | ||||
| Cash And Equivalents | 78.12 M | ||||
| Cash Per Share | 1.12 X | ||||
| Total Debt | 26.83 M | ||||
| Debt To Equity | 1.12 % | ||||
| Current Ratio | 6.97 X | ||||
| Book Value Per Share | (0.76) X | ||||
| Cash Flow From Operations | (46.36 M) | ||||
| Earnings Per Share | (2.75) X | ||||
| Market Capitalization | 10.61 M | ||||
| Total Asset | 24.63 M | ||||
| Retained Earnings | (321.07 M) | ||||
| Working Capital | 11.02 M | ||||
| Current Asset | 54.61 M | ||||
| Current Liabilities | 5.15 M | ||||
About Aslan Pharmaceuticals Performance
To evaluate Aslan Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Aslan Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Aslan Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Aslan Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Aslan's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.00 | 0.00 | |
| Return On Tangible Assets | (1.80) | (1.89) | |
| Return On Capital Employed | (3.80) | (3.61) | |
| Return On Assets | (1.80) | (1.89) | |
| Return On Equity | 3.33 | 1.94 |
Things to note about Aslan Pharmaceuticals performance evaluation
Checking the ongoing alerts about Aslan Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aslan Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aslan Pharmaceuticals is way too risky over 90 days horizon | |
| Aslan Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Aslan Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Aslan Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 12 M. Net Loss for the year was (44.22 M) with profit before overhead, payroll, taxes, and interest of 79.82 M. | |
| Aslan Pharmaceuticals Ltd currently holds about 78.12 M in cash with (46.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.12, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Aslan Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Eblasakimab shows promise in atopic dermatitis study |
- Analyzing Aslan Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aslan Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Aslan Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aslan Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aslan Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aslan Pharmaceuticals' stock. These opinions can provide insight into Aslan Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aslan Pharmaceuticals Ltd. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Aslan Stock analysis
When running Aslan Pharmaceuticals' price analysis, check to measure Aslan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aslan Pharmaceuticals is operating at the current time. Most of Aslan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aslan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aslan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aslan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is Aslan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aslan Pharmaceuticals. If investors know Aslan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aslan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.75) | Revenue Per Share 0.729 | Return On Assets (0.64) | Return On Equity (4.27) |
The market value of Aslan Pharmaceuticals is measured differently than its book value, which is the value of Aslan that is recorded on the company's balance sheet. Investors also form their own opinion of Aslan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aslan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aslan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aslan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aslan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aslan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aslan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.